# EPO906 Therapy in Patients With Advanced Colorectal Cancer

> **NCT00035087** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 62 (actual)

## Conditions studied

- Colorectal Neoplasms
- Colonic Neoplasms

## Interventions

- **DRUG:** epothilone b

## Key facts

- **NCT ID:** NCT00035087
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2003-03
- **Final completion:** 2003-03
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00035087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00035087, "EPO906 Therapy in Patients With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00035087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*